November 1-5, 2015
In response to the uncertainty of ever-changing product pipelines, the biotech industry has been driven to develop flexible manufacturing solutions. These facilities can mobilize quickly to provide a nimble response to sudden changes in production demands. The industry has concurrently improved its ability to assess and effectively mitigate risks to manufacturing processes by developing engineering solutions that isolate the bioprocess from the environment housing it. This presentation will illustrate how the implementation of continuous closed bioprocessing impacts the design of biopharmaceutical manufacturing facilities. The impact of closed continuous bioprocessing on facility size, capital cost and operating cost will also be discussed. Finally an overview of the risks and barriers to implementation of continuous closed processing technology will be presented.
Marc Pelletier, "Impact of closed and continuous processing on biopharmaceutical facility layouts" in "Integrated Continuous Biomanufacturing II", Chetan Goudar, Amgen Inc. Suzanne Farid, University College London Christopher Hwang, Genzyme-Sanofi Karol Lacki, Novo Nordisk Eds, ECI Symposium Series, (2015). https://dc.engconfintl.org/biomanufact_ii/73